Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Hironobu, Tadaki"'
Autor:
Chihiro Okuma, Takeshi Ohta, Hironobu Tadaki, Tatsuya Ishigure, Shohei Sakata, Hideyuki Taniuchi, Ryuhei Sano, Hiromi Hamada, Shinichi Kume, Jun Nishiu, Makoto Kakutani
Publikováno v:
Journal of Pharmacological Sciences, Vol 128, Iss 3, Pp 150-157 (2015)
Aim: Monoacyglycerol acyltransferases (MGATs) are known to play important roles in intestinal TG absorption. In contrast, the role of MGATs in the liver is still unclear. We investigated the effects of JTP-103237, a novel MGAT inhibitor, on hepatic M
Externí odkaz:
https://doaj.org/article/4f84e16fc93843638e297033bf9858ca
Autor:
Chihiro Okuma, Takeshi Ohta, Makoto Ito, Hironobu Tadaki, Tomohiro Oda, Shinichi Kume, Jun Nishiu, Makoto Kakutani
Publikováno v:
Journal of Pharmacological Sciences, Vol 130, Iss 2, Pp 136-138 (2016)
Some nutrients, such as carbohydrate, fat and protein, are known to stimulate satiety. However, the effect of sn-2-monoacylglycerol (2-MG), one of the digestive products of triglycerides, on food intake is still unclear. In the present study, the eff
Externí odkaz:
https://doaj.org/article/75e71d1997c94870b15a717a96be6fdf
Autor:
Takahisa Yamada, Kazuhito Harada, Takashi Kawai, Tomohiko Sasase, Yu Motohashi, Sumiaki Fukuda, Nobuya Ogawa, Masao Yamanaka, Naoto Ogawa, Hironobu Tadaki, Yasufumi Toriniwa, Takeshi Ohta
Publikováno v:
Clinical and Experimental Pharmacology and Physiology. 48(3):381-388
G protein-coupled receptor 119 (GPR119) expression in pancreatic β-cells and intestinal L-cells is a potential therapeutic target for the treatment of type 2 diabetes. Previously, we have reported that the GPR119 agonist JTP-109192 improves glucose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29f43a94a8725c54012ebbe8cc863305
http://hdl.handle.net/2433/261718
http://hdl.handle.net/2433/261718
Autor:
Yasutaka Murai, Takeshi Ohta, Hironobu Tadaki, Naoya Imagawa, Shiro Heitaku, Takahisa Yamada, Tomohiko Sasase
Publikováno v:
Clinical and Experimental Pharmacology and Physiology. 47:583-590
Peripheral artery disease (PAD) is defined as peripheral blood flow impairment, especially in the legs, caused by atherosclerotic stenosis. The disease decreases quality of life because of intermittent claudication or necrosis of the leg. The hindlim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f2f3802006e685849a8817aac8d8c395
https://doi.org/10.1111/1440-1681.13239
https://doi.org/10.1111/1440-1681.13239
Autor:
Hiromi Yoshiuchi, Hironobu Tadaki, Chihiro Okuma, Reina Kakefuda, Takeshi Ohta, Yukihito Ishii, Daisuke Tomimoto, Mariko Maekawa, Ryuhei Sano, Yoshiaki Katsuda, Tomohiko Sasase
Publikováno v:
Biological and Pharmaceutical Bulletin. 42:1906-1912
Tumor necrosis factor-α (TNF-α) converting enzyme/a disintegrin and metalloproteinase domain-containing protein 17 (TACE/ADAM17) is a key sheddase that releases TNF-α from its inactive precursor and is thought as a new drug target to inhibit TNF-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::483eb128e9f50cd62b7365039ba59613
https://doi.org/10.1248/bpb.b19-00526
https://doi.org/10.1248/bpb.b19-00526
Autor:
Takahisa Yamada, Takeshi Ohta, Kazuhito Harada, Hironobu Tadaki, Yasufumi Toriniwa, Sumiaki Fukuda, Tomohiko Sasase
Publikováno v:
Clinical and Experimental Pharmacology and Physiology. 46:910-919
G-protein coupled receptor 119 (GPR119) expression in pancreatic β-cells and intestinal L cells is a potential therapeutic target for treating type 2 diabetes. A natural GPR119 agonist oleoylethanolamide is well known to enhance a glucose-stimulated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d60e0b5e705e5da0f0e195943d2213e
https://doi.org/10.1111/1440-1681.13152
https://doi.org/10.1111/1440-1681.13152
Autor:
Hironobu Tadaki, Yu Motohashi, Shinichi Kume, Tatsuya Maekawa, Tomohiko Sasase, Katsuhiro Miyajima, Takeshi Ohta
Publikováno v:
Journal of Pharmacological and Toxicological Methods. 88:160-166
Introduction To establish an animal model for diabetic peripheral neuropathy (DPN) at an earlier stage, we performed functional and pathophysiological evaluations in Spontaneously Diabetic Torii (SDT) fatty rats before 16 weeks of age. Methods Male S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7dac08d976610e98b9740cec8ceb7c6
https://doi.org/10.1016/j.vascn.2017.09.257
https://doi.org/10.1016/j.vascn.2017.09.257
Autor:
Mariko, Maekawa, Hironobu, Tadaki, Daisuke, Tomimoto, Chihiro, Okuma, Ryuhei, Sano, Yukihito, Ishii, Yoshiaki, Katsuda, Hiromi, Yoshiuchi, Reina, Kakefuda, Takeshi, Ohta, Tomohiko, Sasase
Publikováno v:
Biologicalpharmaceutical bulletin. 42(11)
Tumor necrosis factor-α (TNF-α) converting enzyme/a disintegrin and metalloproteinase domain-containing protein 17 (TACE/ADAM17) is a key sheddase that releases TNF-α from its inactive precursor and is thought as a new drug target to inhibit TNF-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5ddb819218037984ca0c3b9366095988
https://pubmed.ncbi.nlm.nih.gov/31685773
https://pubmed.ncbi.nlm.nih.gov/31685773
Autor:
Yasutaka, Murai, Tomohiko, Sasase, Hironobu, Tadaki, Shiro, Heitaku, Naoya, Imagawa, Takahisa, Yamada, Takeshi, Ohta
Publikováno v:
Clinical and experimental pharmacologyphysiologyREFERENCES. 47(4)
Peripheral artery disease (PAD) is defined as peripheral blood flow impairment, especially in the legs, caused by atherosclerotic stenosis. The disease decreases quality of life because of intermittent claudication or necrosis of the leg. The hindlim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::481ded296b97eda284760bf540b70fb9
https://pubmed.ncbi.nlm.nih.gov/31868944
https://pubmed.ncbi.nlm.nih.gov/31868944